Economic burden of psoriasis and potential cost offsets with biologic treatment : A swedish register analysis
(2016) In Acta Dermato-Venereologica 96(5). p.651-657- Abstract
Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were... (More)
Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were estimated at USD 23,293 (95% confidence interval (95% CI) 22,372−24,199). This cost was partially offset, with savings in direct costs estimated to range from USD –1,135 (95% CI –2,050 to –328) to USD –4,422 (95% CI –6,552 to –2,771), depending on assumptions. The corresponding estimates for indirect costs savings were from USD –774 (95% CI –2,019−535) to USD –1,875 (95% CI –3,650 to –188). The study suggests that psoriasis is associated with substantial costs, which may be modifiable with treatment.
(Less)
- author
- Svedbom, Axel ; Dalén, Johan ; Mamolo, Carla ; Cappelleri, Joseph C. ; Mallbris, Lotus ; Petersson, Ingemar F. LU and Ståhle, Mona
- organization
- publishing date
- 2016-06-15
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Biologics, Cost savings, Cost-of-illness, Psoriasis
- in
- Acta Dermato-Venereologica
- volume
- 96
- issue
- 5
- pages
- 7 pages
- publisher
- Medical Journals Limited
- external identifiers
-
- scopus:84973598001
- pmid:26716136
- wos:000378883900012
- ISSN
- 0001-5555
- DOI
- 10.2340/00015555-2329
- language
- English
- LU publication?
- yes
- id
- f945bfd8-6ca5-4c5c-9ec0-4f7cc566c8b6
- date added to LUP
- 2016-07-12 15:22:30
- date last changed
- 2024-04-19 06:03:09
@article{f945bfd8-6ca5-4c5c-9ec0-4f7cc566c8b6,
abstract = {{<p>Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were estimated at USD 23,293 (95% confidence interval (95% CI) 22,372−24,199). This cost was partially offset, with savings in direct costs estimated to range from USD –1,135 (95% CI –2,050 to –328) to USD –4,422 (95% CI –6,552 to –2,771), depending on assumptions. The corresponding estimates for indirect costs savings were from USD –774 (95% CI –2,019−535) to USD –1,875 (95% CI –3,650 to –188). The study suggests that psoriasis is associated with substantial costs, which may be modifiable with treatment.</p>}},
author = {{Svedbom, Axel and Dalén, Johan and Mamolo, Carla and Cappelleri, Joseph C. and Mallbris, Lotus and Petersson, Ingemar F. and Ståhle, Mona}},
issn = {{0001-5555}},
keywords = {{Biologics; Cost savings; Cost-of-illness; Psoriasis}},
language = {{eng}},
month = {{06}},
number = {{5}},
pages = {{651--657}},
publisher = {{Medical Journals Limited}},
series = {{Acta Dermato-Venereologica}},
title = {{Economic burden of psoriasis and potential cost offsets with biologic treatment : A swedish register analysis}},
url = {{http://dx.doi.org/10.2340/00015555-2329}},
doi = {{10.2340/00015555-2329}},
volume = {{96}},
year = {{2016}},
}